ICD-10-CM 2026 · Effective October 1, 2025

ICD-10 E22.0

Billable / Specific HCC v28: 23

Acromegaly and pituitary gigantism

E22
Block
1
Synonyms
131
LCDs
10
Payer Policies
1
Linked CPTs

About ICD-10-CM E22.0

ICD-10-CM code E22.0 represents Acromegaly and pituitary gigantism. This is a billable/specific code in the Endocrine, Nutritional, and Metabolic chapter (block E22). The 2026 edition of ICD-10-CM E22.0 became effective on October 1, 2025.

Coding Tips for E22.0

Specialist guidance from the PayerReady Medical Coding Team. Specificity warnings, HCC capture rules, sequencing notes.

HCC capture: document with MEAT each year

E22.0 is a CMS-HCC v28 risk-adjustment code (category 23). To count for the patient Risk Adjustment Factor (RAF), document the diagnosis with MEAT language each calendar year: Monitored, Evaluated, Assessed, Treated. A diagnosis on the problem list alone does not satisfy CMS RADV audit standards. Include the diagnosis in the assessment with current status and current treatment plan.

Inclusion Terms / Approximate Synonyms

Clinical terms and conditions classified under E22.0. Per CMS ICD-10-CM Tabular 2026.

  • Overproduction of growth hormone

Type 1 Excludes

Pure excludes, these codes can never be coded together with E22.0. The conditions are mutually exclusive (e.g., congenital vs acquired forms).

  • constitutional gigantism (E34.4)
  • constitutional tall stature (E34.4)
  • increased secretion from endocrine pancreas of growth hormone-releasing hormone (E16.8)

Medicare Advantage HCC Impact

CMS-HCC v28 (current)
Category 23
ESRD-HCC
Category 23
RxHCC (Part D)
Category 23

Capture this diagnosis annually for accurate risk adjustment. Missed HCC captures are the #1 revenue leak in Medicare Advantage risk programs.

Medicare LCD Coverage for E22.0

Local Coverage Determinations (LCDs) from CMS MACs that list E22.0 as a covered diagnosis.

131 LCDs

Showing top 10 of 131 total . Click a CPT for full coverage scope.

CMS LCD: Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin� LAR Depot)
Article ID: 56531, Effective: 2024-10-01 00:00:00, 72 covered, 0 non-covered
CPT J2353 →
CMS LCD: Billing and Coding: Visual Fields Testing
Article ID: 56551, Effective: 2025-10-01 00:00:00, 1427 covered, 0 non-covered
CPT 92082 →
CMS LCD: Billing and Coding: Visual Fields Testing
Article ID: 56551, Effective: 2025-10-01 00:00:00, 1427 covered, 0 non-covered
CPT 92083 →
CMS LCD: Billing and Coding: Visual Fields Testing
Article ID: 56551, Effective: 2025-10-01 00:00:00, 1427 covered, 0 non-covered
CPT 92081 →
CMS LCD: Billing and Coding: CT of the Head
Article ID: 56612, Effective: 2025-10-01 00:00:00, 7586 covered, 0 non-covered
CPT G2187 →
CMS LCD: Billing and Coding: CT of the Head
Article ID: 56612, Effective: 2025-10-01 00:00:00, 7586 covered, 0 non-covered
CPT G2188 →
CMS LCD: Billing and Coding: CT of the Head
Article ID: 56612, Effective: 2025-10-01 00:00:00, 7586 covered, 0 non-covered
CPT G2195 →
CMS LCD: Billing and Coding: CT of the Head
Article ID: 56612, Effective: 2025-10-01 00:00:00, 7586 covered, 0 non-covered
CPT G2189 →
CMS LCD: Billing and Coding: CT of the Head
Article ID: 56612, Effective: 2025-10-01 00:00:00, 7586 covered, 0 non-covered
CPT G2194 →
CMS LCD: Billing and Coding: CT of the Head
Article ID: 56612, Effective: 2025-10-01 00:00:00, 7586 covered, 0 non-covered
CPT G2193 →

Commercial Payer Coverage

Coverage policies from major commercial payers referencing E22.0.

10 policies

5 Medicare

Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin� LAR Depot)
Policy ID: ART-56531
Billing and Coding: Visual Fields Testing
Policy ID: ART-56551
Billing and Coding: CT of the Head
Policy ID: ART-56612
Billing and Coding: Thoracic Aortography and Carotid, Vertebral, and Subclavian Angiography
Policy ID: ART-56631
Billing and Coding: Visual Fields Testing
Policy ID: ART-56799

2 Aetna

Growth Hormone (GH) and Growth Hormone Antagonists
Policy ID: CPB-0170
Somatostatin Analogs
Policy ID: CPB-0693

CPT Codes Commonly Billed with E22.0

Procedures frequently paired with this diagnosis based on PayerReady's Dx↔Px linkage data.

1 linkages
  • J2353 CMS LCD: Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin� LAR Depot) CMS LCD

Convert E22.0 to ICD-9-CM

Per CMS General Equivalence Mappings (GEMs), useful for legacy data review and historical claim analysis.

ICD-10ICD-9Mapping Flags
E22.0 2530 10000

Flags format (5 digits): Approximate · No Map · Combination · Scenario · Choice List. Source: CMS 2017 GEMs (final version).

ICD-10 E22.0, Billing FAQ

Is ICD-10 code E22.0 billable? +

Yes, E22.0 is a billable ICD-10-CM code that can appear as a primary or secondary diagnosis on claims.

What other names or terms map to E22.0? +

ICD-10 E22.0 includes: Overproduction of growth hormone.

What codes are Type 1 Excludes for E22.0? +

Type 1 Excludes (never code together with E22.0): constitutional gigantism (E34.4); constitutional tall stature (E34.4); increased secretion from endocrine pancreas of growth hormone-releasing hormone (E16.8)

Does E22.0 affect Medicare Advantage HCC risk adjustment? +

Yes. E22.0 maps to CMS-HCC v28 category 23. Capture this diagnosis annually for accurate Medicare Advantage risk score.

What CPT codes are commonly billed with E22.0? +

Procedures frequently paired with E22.0 include: J2353.

What ICD-9 codes does E22.0 map to? +

Per CMS GEMs, E22.0 maps to ICD-9 codes: 2530. Useful for legacy data review and historical claim analysis.

Get the full PayerReady toolkit

Free access to CPT/ICD-10 lookup, denial appeals, fee comparator, and claim auditing with credentialing enrollment.

Start free →

Run this code through our claim audit tool

Check NCCI bundling, MUE limits, and modifier logic before submission.

Try the auditor →

Did this page help?

Quick signal so we know what to improve.

Thanks!

If you want a code reference page that doesn't exist yet, email coding@payerready.com.

Sorry to hear that.

Tell us what's missing or wrong: coding@payerready.com. We respond within 5 business days.

Reviewed by the PayerReady Medical Coding Team

Verified against the CMS 2026 code set on May 31, 2026.

Powered by 11K CPT · 98K ICD-10 · 860K MPFS rates · 4.5M NCCI edits · 9.5M NPIs. Our data methodology · About our coding team

Faster Approvals

Ready to Cut Your Enrollment Timeline in Half?

Join providers in all 50 states who handed off credentialing to a dedicated specialist. Create your free account in minutes and start enrolling the same day.

All 50 States Covered
No Long-Term Contracts
HIPAA HIPAA Compliant Platform
Dedicated Specialist Included